Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cubicin Resistance Should Be Closely Monitored In Bacteremia Patients

Executive Summary

Labeling regarding use of Cubist's anti-infective Cubicin in Staphylococcus aureus patients should include a recommendation for close monitoring for development of resistance, members of FDA's Anti-Infective Drugs Advisory Committee said March 6

You may also be interested in...

Cubist Boosts Cubicin Sales Reps, Will Detail 80% Of Vancomycin Prescribers

Cubist will increase its Cubicin (daptomycin) sales force by one third in the first quarter, bringing the total to 100 reps, CEO Michael Bonney said

FDA Moving Forward On Primary Bacteremia Indication

FDA will continue work on defining an indication for primary bacteremia due to Staph aureus (PBSA) after the agency found support for the claim from the Anti-Infective Drugs Advisory Committee

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts